These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497 [TBL] [Abstract][Full Text] [Related]
44. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Kang KW; Lee BH; Jeon MJ; Yu ES; Sik Kim D; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS Ther Adv Hematol; 2020; 11():2040620720966882. PubMed ID: 35154623 [TBL] [Abstract][Full Text] [Related]
45. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134 [TBL] [Abstract][Full Text] [Related]
46. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. Mei M; Aldoss I; Marcucci G; Pullarkat V Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168 [TBL] [Abstract][Full Text] [Related]
47. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia. Maiti A; Konopleva MY Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368 [TBL] [Abstract][Full Text] [Related]
48. Hypomethylating agents with venetoclax: have we discovered the holy grail? Gutman JA; Pollyea DA Curr Opin Hematol; 2020 Mar; 27(2):76-80. PubMed ID: 31895103 [TBL] [Abstract][Full Text] [Related]
49. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia. Liang P; Xie Y; Liu Z; Wang D; Li Q; Lu Y; Xue S; Wang Y; Chen S; Wu D; Fu J Br J Haematol; 2024 Apr; 204(4):1219-1226. PubMed ID: 38180132 [TBL] [Abstract][Full Text] [Related]
50. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404 [TBL] [Abstract][Full Text] [Related]
51. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778 [No Abstract] [Full Text] [Related]
52. Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years. Avcu G; Karadas N; Goktepe SO; Bal ZS; Metin DY; Polat SH; Aydinok Y; Karapinar DY J Pediatr Hematol Oncol; 2023 Oct; 45(7):392-397. PubMed ID: 37526370 [TBL] [Abstract][Full Text] [Related]
53. D-index and invasive fungal infections (IFIs) in adult acute myeloid leukemia (AML) patients with the first episode of febrile neutropenia. Rattanathammethee T; Munsamai K; Punnachet T; Hantrakun N; Piriyakhuntorn P; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L PLoS One; 2023; 18(5):e0286089. PubMed ID: 37216345 [TBL] [Abstract][Full Text] [Related]
54. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G; Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409 [TBL] [Abstract][Full Text] [Related]
55. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine. Zhang A; Johnson T; Abbott D; Phupitakphol T; Gutman JA; Pollyea DA; Koullias Y Open Forum Infect Dis; 2022 Oct; 9(10):ofac486. PubMed ID: 36225746 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia. Machherndl-Spandl S; Vockenhuber T; Binder M; Weltermann A; Apfalter P; Lass-Flörl C; Girschikofsky M Leuk Lymphoma; 2022 Oct; 63(10):2330-2335. PubMed ID: 35561263 [TBL] [Abstract][Full Text] [Related]
57. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862 [TBL] [Abstract][Full Text] [Related]
58. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Jonas BA; Pollyea DA Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431 [TBL] [Abstract][Full Text] [Related]
59. Venetoclax in AML: Where We Are and Where We Are Headed. Pollyea DA Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856 [TBL] [Abstract][Full Text] [Related]
60. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]